Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments

Roivant Sciences Ltd.

Settlement resolves all US and international patent infringement litigation between Genevant/Arbutus and Moderna over LNP technology in COVID-19 and other mRNA vaccines.
Moderna receives broad license to Genevant/Arbutus patent rights for defined Moderna Licensed Products, including SPIKEVAX, mNEXSPIKE, mRESVIA, and certain other mRNA vaccines.
Moderna will make a noncontingent lump-sum payment (amount redacted) and a contingent payment tied to the outcome of Moderna's appeal on the §1498 government-contractor defense.
Parties stipulate to dismissal of US and ex-US litigation with prejudice; Moderna retains right to appeal only on the §1498 Disputed Matter.
Moderna agrees not to challenge validity/enforceability of specified patents owned by Genevant/Arbutus.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, "Moderna") (effective 2026-03-03).

Action: entry
Agreement: settlement
Counterparty: Moderna, Inc. and ModernaTx, Inc. (together, "Moderna")
Effective: 2026-03-03

Exact text from the filing

on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.

View on SEC.gov

Browse all material agreements →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-26-010656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.